B-cell Non-Hodgkin's Lymphoma (NHL): Worldwide Market Insights, Epidemiology and Forecast to 2028 - ResearchAndMarkets.com

The "B-cell Non-Hodgkin's Lymphoma - Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of B-cell NHL in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

B-cell NHL Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incidence of NHL, Total Incidence cases of B cell-NHL, Gender-specific Incidence of B-cell NHL, Age-specific Incidence of B-cell NHL, Subtype - Specific Incidence of B-cell NHL and Stage-Specific Incidence of B-cell NHL] scenario of B-cell NHL in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2028.

Analysts have assessed that the total prevalent population of B-cell NHL in the 7MM was 141,873 in 2017. In addition to this, there was a gender difference in the disease. It was seen that, the B-cell lymphoma cases occurs more frequently in male population as compared to female. In 2017, a more number of males were affected by the disease, i.e., 55% of the B-cell NHL cases in the 7MM, which is equivalent to 78,030 cases in comparison to the females.

Drug Chapters

The treatment of B-cell NHL is mainly based on the subtype and stage of the disease, according to the subtype and stage of the disease, initial therapy and intensity of treatment taken into consideration. In general, the goal of treatment is to destroy as many lymphoma cells as possible and to induce complete remission. Treatment can also keep non-Hodgkin lymphoma (NHL) in check for many years, even though imaging or other studies show the remaining sites of disease. This situation may be referred to as a partial remission.

For patients without symptoms and with indolent subtypes of B-cell NHL, the treatment may be the watch-and-wait approach, meaning treatment is deferred or delayed until signs of disease progression occur. Frequent and careful observation is required so that effective treatment can be started if the disease starts advancing. Some patients have a long-time slow-growing disease, while others have a condition that evolves (transforms) into a more aggressive type of B-cell NHL that requires immediate treatment.

In general, chemotherapy and radiation therapy are the two principal forms of treatment for B-cell NHL. Although radiation therapy is often neither the sole nor the principal curative therapy, it is an important additional treatment in some cases.

The current treatment approaches include Rituximab based mono and combination therapies, Monoclonal antibodies based regimen except Rituximab, Immune Checkpoint inhibitors, Immunomodulators, Proteasome inhibitors, Kinase inhibitors, CAR-T cell therapies, and Histone deacetylase (HDAC) inhibitors.

The following drugs are approved under abovementioned classes, Brukinsa (Zanubrutinib, a product of BeiGene), Polivy (Polatuzumab vedotin, a product of Hoffmann-La Roche), Venetoclax (ABT199, a product of AbbVie and Roche), Kymriah (tisagenlecleucel, a product of Novartis), Yescarta (Axicabtagene ciloleucel, a product of Gilead Sciences), Aliqopa (Copanlisib, a product of Bayer), Imbruvica (Ibrutinib, a product of Janssen/Pharmacyclics (AbbVie Company)), Zydelig (Idelalisib, a product of Gilead Sciences), Gazyva (Obinutuzumab, a product of Genentech, Roche Group), Zevalin (ibritumomab tiuxetan, a product of Spectrum Pharmaceuticals), Velcade (bortezomib, a product of Takeda (Millennium Pharmaceuticals) and Janssen Pharmaceutical), Revlimid (lenalidomide, a product of Celgene Corporation) and others.

Market Outlook

The market size of B-cell NHL in seven major markets (7MM) is estimated to be USD 4,103 million in 2017. The United States accounts for the highest market size of B-cell NHL in comparison to the other major markets i.e., EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while Spain had the lowest market size of B-cell NHL in 2017.

Drugs Uptake

With the launch of emerging therapies like Lisocabtagene maraleucel (JCAR017, a product of Bristol-Myers Squibb), which is an anti-CD-19-directed CAR T-cell product administered intravenously in defined composition at a precise dose of CD8 and CD4 CAR T cells which induced durable responses in poor-prognosis patients with R/R aggressive NHL after at least two prior therapies, KTE-X19 (Gilead Sciences), Tafasitamab (MOR208, a product of MorphoSys AG), Tazemetostat (E7438, a product of Epizyme), Abexinostat (Xynomic Pharmaceuticals), Umbralisib (TG Therapeutics), Avelumab (Pfizer/Merck) and others, the market of B-cell NHL is anticipated to change during the forecast period (2019-2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by Analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of B-cell NHL will have better management practices.

According to our assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019-2028], and with their anticipated launch, the market size of B-cell NHL will also experience significant growth.

Companies Mentioned

• AbbVie
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Epizyme
• Gilead Sciences
• Hoffmann-La Roche
• Janssen
• Merck
• MorphoSys AG
• Novartis
• Pfizer
• Spectrum Pharmaceuticals
• Takeda
• Xynomic Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/z1lgfo

View source version on businesswire.com: https://www.businesswire.com/news/home/20200424005463/en/